Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.50 |
| ▸ | FAAH | O00519 | 11/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | AADAC | P22760 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588061 | 0.86 | EPHX2 (0.47) | EPHX2FAAHEPHX1HRH3 | |
| SCHEMBL20588755 | 0.81 | CHRM4 (0.46) | EPHX2EPHX1HRH3 | |
| SCHEMBL2089684 | 0.77 | EPHX2 (0.60) | EPHX2FAAHMMP2MMP13AADAC | |
| SCHEMBL19538662 | 0.77 | HRH3 (0.61) | HRH3 | |
| SCHEMBL3334541 | 0.77 | EPHX2 (0.64) | EPHX2FAAHMMP2MMP13AADAC | |
| SCHEMBL3028128 | 0.73 | POLB (0.56) | EPHX2FAAHMMP2MMP13HRH3 | |
| SCHEMBL6097817 | 0.73 | EPHX2 (0.56) | EPHX2FAAHMMP2MMP13AADAC | |
| SCHEMBL2056114 | 0.72 | HRH3 (0.58) | EPHX2FAAHMMP2MMP13HRH3 | |
| SCHEMBL2089682 | 0.72 | EPHX2 (0.54) | EPHX2FAAHMMP2MMP13AADAC | |
| SCHEMBL17422617 | 0.72 | EPHX2 (0.44) | EPHX2FAAHMMP2MMP13AADAC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018229683-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2018-12-20 | — | — | WO | disclosed |